Boom! Another unicorn pops up from India as Groww raises $83 million at a billion dollar valuation
- Online investment platform Groww has raised $83 million at a billion dollar valuation from Tiger Global.
- The investment also saw participation from existing investors Sequoia India, Ribbit Capital, YC Continuity and Propel Venture Partners.
- Groww becomes the fourth unicorn in this week alone and the eighth unicorn of 2021 so far.
The startup had last raised $30 million in Series C led by YC Continuity in September 2020.
With this, Groww becomes the fourth startup to be catapulted to unicorn status this week alone and the eighth unicorn of 2021, so far.
|Digit Insurance||January 15|
|Five Star Business Finance||March 27|
Groww is a stockbroking startup founded by former Flipkart employees – Lalit Keshre, Harsh Jain, Neeraj Singh, and Ishan Bansal. Based in Bengaluru, the company claims to have over 10 million registered users across 900 cities.
The four-year old startup was also a part of CB Insights’ list of 250 world’s most promising fintech companies.
The stock broking market has been heating up as India has seen a huge uptick in the number of people investing in Indian stock markets. Groww faces competition from the likes of Zerodha, Paytm Money, INDMoney, Stockal among others.
With the latest investment, the startup plans to expand its product suite, hire top-quality talent, and invest heavily in financial education and awareness.
OYO says an angry creditor has dragged the $9 billion startup to court over a ₹16 lakh dispute
For the third consecutive day, a new unicorn is born from India as PharmEasy joins the billion dollar club
- By air, rail and road – how oxygen is being transported across India amidst a severe COVID-19 crisis
- Voice search queries in India are growing at 270% per year: MMA and Isobar Report
- Mukesh Ambani's Reliance Industries buys Britain's iconic country club Stoke Park for ₹592 crore
- Instagram is bringing ads to Reels in India; here are a few formats it is planning to add
- Simplified: AIIMS, ICMR new guidelines for treatment of patients with ‘moderate’ case of COVID-19